PKC-d is a serine/threonine kinase that mediates diverse signal transduction pathways. We previously demonstrated that overexpression of PKC-d slowed the G1 progression of Caco-2 colon cancer cells, accelerated apoptosis, and induced cellular differentiation. In this study, we further characterized the PKC-d dependent signaling pathways involved in these tumor suppressor actions in Caco-2 cells overexpressing PKC-d using a Zn 2 þ inducible expression vector. Consistent with a G1 arrest, increased expression of PKC-d caused rapid and significant downregulation of cyclin D1 and cyclin E proteins (50% decreases, Po0.05), while mRNA levels remained unchanged. The PKC agonist, phorbol 12-myristate 13-acetate (TPA, 100 nM, 4 h), induced two-fold higher protein and mRNA levels of p21
Introduction
Colorectal cancer is the third leading cause of cancerrelated deaths in the United States (Greenlee et al., 2000) . The molecular events in colon cancer involve a stepwise accumulation of activating mutations in protooncogenes, such as K-ras, and inactivating mutations of tumor suppressor genes, such as APC (Fearon and Vogelstein, 1990) , together with nonmutational changes in many effectors including protein kinase C (PKC). The PKC family regulates colonic crypt cell fate, with proliferation at the base, progressive maturation along the ascending crypt axis and apoptosis at the colonic luminal surface (Shanmugathasan and Jothy, 2000) . The PKC family is comprised of at least 11 isoforms (Nishizuka, 1995) . Members of this family are classified into three groups, distinguished by differences in sequence homology and cofactor requirements for activation (Newton, 1997) . While all isoforms require acidic phospholipids (phosphatidylserine), the conventional PKCs (a, bI, bII, and g) are activated by calcium (Ca 2 þ ) and 1,2-diacyl-sn-glycerol (DAG), whereas the novel class of PKCs (d, e, y, and Z) are Ca 2 þ -independent, but DAG-dependent. The atypical PKCs (l, z, and i) are not regulated by Ca 2 þ or DAG (Liu and Heckman, 1998) . In addition to these structural and regulatory differences, PKC isoforms exhibit distinct patterns of tissue expression and subcellular localization, supporting the current belief that these kinases mediate unique cell-specific functions (Wetsel et al., 1992; Newton, 1997) .
In normal colonic mucosa, the expression levels of several PKC isoforms follow an increasing gradient from the base of the crypt to the mucosal surface, paralleling crypt cell maturation (Black, 2001) . While PKC signaling regulates postmitotic events during normal intestinal epithelial cell maturation (Saxon et al., 1994) , derangements in PKC isoforms are also thought to contribute to colonic malignant transformation. For example, PKC a, bI, d and z are decreased at different stages of neoplastic progression (Weinstein, 1991; McGarrity and Peiffer, 1994; Kahl-Rainer et al., 1994 Brasitus and Bissonnette, 1998; Verstovsek et al., 1998; Black, 2001) . These changes in specific isoforms suggest that PKC signal dysregulations contribute to neoplastic transformation. Consistent with a potential tumor suppressor role for PKC-d, a number of studies have reported that several proto-oncogenes transform cells, at least in part, by causing the loss of PKC-d activity (Geiges et al., 1995; Li et al., 1996 Li et al., , 1998 Lu et al., 1997; Zang et al., 1997) . Conversely, overexpression of PKC-d inhibited the transformed phenotype of src-overexpressing rat colonic epithelial cells, causing an arrest in cellular proliferation (Perletti et al., 1999) . In vitro overexpression of PKC-d has been associated with decreased growth and enhanced differentiation and cell death in several noncolonic cell lines (Gschwendt, 1999; Kikkawa et al., 2002; Brodie and Blumberg, 2003; Jackson and Foster, 2004) . Our own studies, moreover, have established that PKC-d regulates the growth phenotype in Caco-2 colon cancer cells (Cerda et al., 2001) . This human colon cancer cell line has been extensively studied as a model of intestinal epithelial cell biology (Pinto et al., 1983; Evers et al., 1996; Abraham et al., 1998; Ding et al., 1998; ScaglioneSewell et al., 1998) . Using stable transfectants with cDNA coding for full-length PKC-d, we examined the biological consequences of alterations in the expression of PKC-d on the neoplastic phenotype of these cells using two different Zn 2 þ -inducible metallothionein eukaryotic expression vectors (Cerda et al., 2001) . We showed that PKC-d upregulation in Caco-2 cells, a condition more closely resembling nontransformed colonocytes, attenuated the transformed phenotype. Effects of PKC-d upregulation included inhibited anchorage-dependent and -independent growth, G1 cell cycle slowing, increased differentiation, and enhanced apoptosis. Based on our studies in these cells, the observed loss of PKC-d in colon cancers would appear to provide a clear growth advantage for transforming colonocytes and contribute to the dysregulated growth characterizing colonic carcinogenesis (Black, 2001) .
In agreement with our prior studies showing PCK-d slowed G1 progression, there is increasing evidence that PKC regulates the cell cycle through multiple pathways (Arita et al., 1998; Toyoda et al., 1998; Besson and Yong, 2000; Graham et al., 2000; Zhu et al., 2000; Shanmugam et al., 2001; Wakino et al., 2001 ; Acevedo- Duncan et al., 2002; Kikkawa et al., 2002; La Porta et al., 2002; Lee et al., 2002; Lin et al., 2002; Brodie and Blumberg, 2003; Soh and Weinstein, 2003; Avazeri et al., 2004; Clark et al., 2004; Gavrielides et al., 2004; Leontieva and Black, 2004; Atten et al., 2005) . In nontransformed rat intestinal epithelial crypt cells, PKC signaling mediates cell cycle exit through rapid downregulation of G1 cyclins and increased expression of Cip/Kip cyclin-dependent kinase inhibitors (Frey et al., 1997 (Frey et al., , 2000 Clark et al., 2004) . Studies in noncolonic cellular systems have demonstrated that PKC-d inhibits proliferation by suppressing G1 cyclin expression and increasing expression of cyclin-dependent kinase (cdk) inhibitors (Weinstein, 1991; Fukumoto et al., 1997; Toyoda et al., 1998; Ashton et al., 1999; Shanmugam et al., 2001; Page et al., 2002; Nakagawa et al., 2005) . However, the effects of this isoform on the growth phenotype depend upon the cellular context. In rat 3Y1 fibroblasts, for example, PKC-d promotes cell cycle progression in late G1, in addition to negatively regulating M phase entry (Kitamura et al., 2003) . In contrast, in rat thyroid cells, this isoenzyme stimulates apoptosis by initiating G1 phase cell cycle progression while arresting cells in S phase (Santiago-Walker et al., 2005) . The role of PKC-d in cell death has also been investigated in many cellular systems (Kikkawa et al., 2002; Brodie and Blumberg, 2003; Wang et al., 2003; Jackson and Foster, 2004) . Studies have demonstrated that PKC-d promotes cell death in many noncolonic cell lines, including keratinocytes (Denning et al., 1998) , neutrophils (Pongracz et al., 1999) , cerebral granule cells (Villalba, 1998) , HL-60 and prostate cancer cells (Savickiene et al., 1999; Yin et al., 2005) , but not in breast cancer cells (McCracken et al., 2003; Nabha et al., 2005) . In studies in colonic cells, PKC signaling pathways are also involved in cell cycle and cell death regulation (Goldstein et al., 1995; Qiao et al., 1996; Sauma et al., 1996; Abraham et al., 1998; Perletti et al., 1998 Perletti et al., , 1999 Andre et al., 1999; Assert et al., 1999; Weller et al., 1999; Umar et al., 2000; Cerda et al., 2001; Lin et al., 2002; McMillan et al., 2003; Di Mari et al., 2005; Meyer et al., 2005) . Several studies, including our own investigations, have demonstrated a tumor suppressor role for PKC-d in colon cancer cells, including cell cycle arrest and enhanced apoptosis (Weller et al., 1999; Cerda et al., 2001; Lin et al., 2002; McMillan et al., 2003; Perletti et al., 2004 Perletti et al., , 2005 . There is, however, at least one report that inhibition of this isoenzyme is sufficient to promote cell death (Lewis et al., 2005) . Moreover, recent studies indicate that PKC-d can mediate antiapoptotic signals in some colon cancer cells (Wang et al., 2004 (Wang et al., , 2006 . Thus, PKC-d signaling can drive growth promotion or inhibition, and enhance or inhibit apoptosis in cell context-specific manners.
We previously showed that PKC-d causes a cell cycle arrest in G1 and enhances apoptosis in Caco-2 colon cancer cells (Cerda et al., 2001) . While the downstream targets that mediate these tumor suppressor actions of PKC-d are currently not well recognized in colon cancer cells, we speculated that they involve key regulatory elements of cell cycle control and apoptosis. To further elucidate the mechanisms controlling these processes, in this study, we directly examined G1 cell cycle and cell death regulators that might contribute to the antiproliferative actions of PKC-d in Caco-2 cells. These cells do not contain mutations in c-K-ras or c-src, upstream regulators of PKC that might otherwise confound mechanistic interpretations of effects observed following PKC-d overexpression. We identified PKC-d mediated alterations in several important regulators involved in cell cycle and cell death controls in Caco-2 cells, which would be expected to attenuate the malignant phenotype of these cells. These changes include downregulation of cyclin D1 and cyclin E expression, and upregulation of cyclin cdk inhibitor, p21
Waf1 . These alterations were accompanied by decreased cyclins and increased cdk inhibitors co-associating with G1 cdks. Changes in apoptosis regulators included decreases in antiapoptotic Bcl-2 and increases in proapoptotic Bax. Using siRNA oligonucleotide strategies, as an independent strategy, we also demonstrate a direct role for PKC-d in the downregulation of cyclin D1 and cyclin E expression, and upregulation of Bax. These results, and a discussion of their implications in colonic carcinogenesis, form the basis for the current study.
Results
In previous studies we demonstrated overexpression of PKC-d inhibited proliferation, enhanced differentiation and accelerated apoptosis in Caco-2 colon cancer cells (Cerda et al., 2001) . The inhibited proliferation induced by PKC-d involved both a selective cell cycle arrest in G1 and enhanced apoptosis (Cerda et al., 2001) . In this study, we further characterized the signaling pathways involved in the tumor suppressor actions of this isoenzyme in Caco-2 cells transfected with PKC-d under the control of a Zn 2 þ inducible metallothionein promoter.
Activation of PKC-d inhibits cellular proliferation and causes cell cycle slowing in G0/G1 and increased cell death in Caco-2 cells To extend our previous studies and further elucidate the role PKC-d plays in control of cell cycle and cell death in colon cancer cells, we initially investigated the function of this isoenzyme in control of Caco-2 colonic cell proliferation. As shown in Figure 1 , PKC-d overexpression caused a significant 30% decrease in cell proliferation relative to empty vector (EV) transfected cells (Po0.05, n ¼ 6). We then treated cells with 12-Otetradecanoylphorbol 13-acetate (TPA), a phorbol ester, known to activate classical and novel PKC isoforms (Castagna et al., 1982; Ryves et al., 1991) , or with Bistratene A (BisA), a PKC-d specific activator (Watters et al., 1998) . Treatment of EV transfected Caco-2 cells with TPA or with BisA for 48 h, significantly inhibited cellular proliferation by 33 and 29%, respectively, compared with DMSO (vehicle treated) controls (Po0.05, n ¼ 6). When Caco-2 cells overexpressing PKC-d were treated with these agonists, cellular proliferation was further significantly inhibited at 24 and 48 h. By 48 h, PKC-d agonists TPA and BisA inhibited cellular proliferation by 50 and 64%, respectively, compared with untreated EV controls (Po0.01, n ¼ 6). These agonists caused similar effects on cell proliferation as assessed by BrdU incorporation (data not shown). As an independent confirmation of the direct role PKC-d plays in Caco-2 cell proliferation, we knocked down this isoenzyme using siRNA oligonucleotides that specifically targeted human PKC-d (Irie et al., 2002) . These siRNAs have successfully inhibited PKC-d mRNA by more than 80% in both HEK-293 and HeLa cells (Irie et al., 2002) and also inhibited PKC-d in Caco-2 cells (see below, Figure 6 ). As shown in Figure 2 , knockdown of PKC-d with specific, but not irrelevant random sequence oligonucleotides (control), increased Caco-2 cell proliferation by 140 and 225%, as determined by DNA labeling and mitochondrial activity respectively, compared to control cells (Po0.05). This is consistent with our previous results that PKC-d upregulation (and kinase activation) inhibited Caco-2 cell proliferation.
We previously demonstrated that PKC-d overexpression in the absence of Caco-2 cell treatments caused a 20% increase in the number of Caco-2 cells in the G0/G1 phase of the cell cycle (Cerda et al., 2001 ). In the current study, we examined the effects of TPA or BisA on transfected Caco-2 cells. Caco-2 transfectants were trypsinized, and replated at lower confluency to induce a large fraction to enter S phase. As shown in Table 1 (Livneh and Fishman, 1997; Fishman et al., 1998; Black, 2000) , we attribute TPA-induced G1 slowing in our Caco-2 transfectants to the activation of PKC-d, since the nontargeted isoforms did not differ in expression among parental, EV, and PKC-d transfectants (Cerda et al., 2001) . By 48 h of phorbol ester treatment, there was decreased proliferation in EV and PKC-d transfectants that we speculate arises from downregulation of growth-promoting PKC isoforms that result in an overall decrease in cellular proliferation (Figure 1 ). We then confirmed and extended our previous studies that showed PKC-d overexpression increased programmed cell death in Caco-2 cells (Cerda et al., 2001) . As shown in Table 1 Together, these studies suggest that PKC-d inhibits cellular proliferation in Caco-2 cells via two distinct pathways, slowing cell cycle progression in G0/G1 and increasing the apoptotic rate of these cells.
PKC-d decreases in cyclin D1
and cyclin E, contributing to the G1 arrest in Caco-2 cells The cell cycle is regulated by the coordinated actions of cyclin-dependent kinases, phosphatases and cell cycle inhibitors (King et al., 1996) . The major cyclin-cdk complexes involved in cell cycle progression from the G1 to the S phase are cyclin D-cdk4, 6 and cyclin E-cdk2 (Sherr and Roberts, 1999) . We next asked whether alterations in these important G1 phase regulators might mediate the PKC-d-dependent G1 slowing. In other cells, PKC-isoforms, -a, -d, -e, and -Z, are known to regulate G1 cyclin expression (Fima et al., 2001; Soh and Weinstein, 2003) . To analyse the expression of these cyclins, whole-cell lysates were prepared from EV and . The x-axis shows treatment groups. Each value is calculated from 10 identically treated wells (including controls). Control cells were treated with 50 or 100 nM scrambled oligonucleotide. There were no differences in proliferation between 50 and 100 nM scrambled oligonucleotide. Data are from a representative experiment repeated two times. * ,z Po0.05, compared with appropriate controls (50 or 100 nM oligonucleotide treated). Caco-2 cells, transfected with empty vector (EV) or full-length human PKC-d, were treated for 15-24 h with 100 nM TPA, 100 nM BisA, or DMSO (vehicle) in the presence of zinc. Cells were fixed and analysed for their distribution in the cell cycle using a FacScan flow cytometer and CellQuest software. Distribution of DNA in the cell cycle was determined using Modfit LT software. Apoptotic rates were measured after a period of 48 h. Treated cells were fixed, and nuclei were stained by DAPI and visualized by microscopy. (Li et al., 1997; Parekh et al., 1999; Srivastava et al., 2002; Rybin et al., 2003; Steinberg, 2004; Seki et al., 2005) . Western blot analysis of whole-cell extracts in Figure (Cerda et al., 2001) . As shown in Figure 4 , in cells overexpressing PKC-d, Western blot analysis of whole-cell extracts demonstrated that expression levels of cyclin D1 and cyclin E proteins were decreased by approximately 60 and 50%, respectively, as compared to EV controls (note: cyclin D1 and cyclin E at zero time point, lanes 1 (EV) and 5 (PKC-d)). In contrast to PKC-d transfectants, where cyclin D1 remained unchanged and cyclin E went down, TPA treatment enhanced cyclin D1 and cyclin E expression 1.5-and 2.0-fold, respectively, in EV cells (Figure 4 , lane 1 vs 3 and 4). This is consistent with phorbol esters accelerating G1-S transitions in EV cells, compared with PKC-d transfectants (Table 1) . We speculate that increased PKC-d signaling suppresses cyclin D1 and cyclin E in PKC-d transfectants, over-riding cyclin upregulation by nontargeted PKC isoforms, as seen in TPA-treated EV cells.
In contrast to PKC-d dependent decreases in cyclin D1 and cyclin E proteins, however, there were no differences in cyclin D1 and cyclin E mRNA expression levels between untreated EV control and PKC-d overexpressing Caco-2 cells, as assessed by quantitative realtime PCR ( Figure 5 ). These results suggest that the changes induced in cyclin D1 and cyclin E protein expression levels by PKC-d involve post-transcriptional mechanisms. Treatment with TPA for 3 h enhanced cyclin D1 and cyclin E mRNA expression 1.8-and 2.3-fold in EV cells, respectively, and 1.6-and 1.7-fold in PKC-d transfectants ( Figure 5 ). Thus, we speculate that one of the mechanisms by which PKC-d inhibits G1 cell cycle progression is by suppressing expression of cyclin D1 and E post-transcriptionally. Additionally, treatment with TPA partially downregulated cyclin E mRNA levels in PKC-d transfectants compared with EV cells, 1.7-vs 2.3-fold respectively, suggesting that upregulated PKC-d also suppresses TPA induction of cyclin E at a transcriptional level.
To more specifically address the effects of PKC-d in regulation of these cyclins, we knocked down this isoenzyme in Caco-2 cells overexpressing PKC-d, using siRNA oligonucleotides that specifically target expression of human PKC-d (Irie et al., 2002) . As shown in Figure 6 , PKC-d knockdown with specific siRNA oligonucleotides, but not irrelevant random sequence oligonucleotides (control), inhibited expression of PKC-d by more than 80%. PKC-d knockdown concomitantly caused a 1.670.3-and 1.870.6-fold increase in cyclin D1 and cyclin E expression, respectively ( Figure 6 , compare lanes 1 and 2 with lanes 3 and 4), consistent with our previous results that upregulation of PKC-d inhibited the expression of these cyclins. This was a specific effect, as highly homologous but nontargeted PKC-z was not changed by PKC-d siRNA oligonucleotides. b-Actin was also unaffected by PKC-d siRNA and equivalent b-actin bands confirmed comparable protein loading.
p21
Waf1 is a downstream mediator of PKC-d in Caco-2 cells During cell division, cyclin-dependent kinases (cdks) are sequentially activated through increased levels of cyclins and decreased levels of cdk inhibitors (King et al., 1996) . We next evaluated the role of cdk inhibitors, p21
Waf1 and p27 Waf1 protein was also accompanied by significantly increased p21
Waf1 mRNA, as assessed by quantitative real-time PCR (Figure 7b) . Within 3 h of treatment, TPA increased p21
Waf1 mRNA expression levels B5-fold in PKC-d transfectants, compared with TPA treated EV control cells (Po0.05, n ¼ 6), indicating that PKC-d drives increases in p21
Waf1 mRNA expression. There were no significant differences in expression levels of p27 Kip1 , but there were important differences in p27 Kip1 -cdk4 co-association (see below for changes in p27
Kip1 co-association). Taken together, these data suggest that reductions induced by PKC-d in cyclin D1 and cyclin E involve post-transcriptional mechanisms, whereas increased p21
Waf1 expression involves transcriptional or mRNA stabilization mechanisms.
To further assess if p21 Waf1 is a downstream mediator of PKC-d in Caco-2 cells, we employed rottlerin, an isoform-specific PKC inhibitor (Gschwendt et al., 1994) . Rottlerin is a specific inhibitor of PKC-d in the range of 3-6 mM, whereas higher concentrations (30-100 mM) are required to inhibit other PKC isoforms (Gschwendt et al., 1994) . As shown in Figure 8a , the cyclindependent kinase inhibitor p21
Waf1 is induced within 4 h by the PKC agonist phorbol 12-myristate 13-acetate (TPA, 100 nM) ( Altered levels of cyclin D1, cyclin E, p27 Kip1 and p21
Waf1 co-associating with cyclin-dependent kinases (cdk-2, -4, and -6) contribute to the PKC-d induced G1 arrest in Caco-2 cells To further elucidate the mechanisms involved in the G1 arrest by PKC-d, we analysed cell cycle regulatory proteins co-associating with cdk-2, -4, and -6. G1-specific kinases are not regulated by changes in kinase expression (Sherr, 1996) . In agreement with these reports, in whole-cell lysates, we confirmed that there were no changes in cdk levels. As shown in Figure 9a , PKC-d transfectants had 50% decreased cyclin E in cdk2 immunoprecipitates compared to EV control cells. Levels of cyclin D1 co-associating with cdk6 immunoprecipitates were 60% lower in PKC-d transfectants, compared to EV cells (Figure 9c ). In contrast, cyclin D1 co-associating with cdk4 did not change (Figure 9b ). Although we observed no alterations in total expression of p27
Kip1 in lysates, overexpression of PKC-d increased binding of p27
Kip1 to cdk4 by 30% (Figure 9b ), but did not alter p27 Kip1 association with cdk2 or cdk6 (Figure 9a and c) . Taken together, decreased levels of cyclin E and cyclin D1 co-associating with cdks-2 and -6, respectively, and increased levels of p27 Kip1 co-associating with cdk-4, are expected to reduce kinase activities of these cdks and inhibit G1-S progression.
Complexes between p21 Waf1 and cdk-4 and -6 were also analysed in Caco-2 transfectants. As shown in Figure 10 , 6 h of TPA treatment increased p21
Waf1 coassociating with cdk-4 and -6 in both EV and PKC-d ransfectants (note: p21 Taken together, our results suggest that PKC-d decreases G1 cell cycle activators, cyclin D1 and cyclin E, and increases G1 cell cycle inhibitors, p21
Waf1 and p27
Kip1 co-associating with G1 cdks. These changes, moreover, are expected to decrease the kinase activities of cylin E-cdk2 and cyclin D1-cdk4 and cyclin D1-cdk6, and thereby mediate the G1 cell cycle slowing induced by PKC-d overexpression in Caco-2 cells.
PKC-d accelerates apoptosis by downregulating Bcl-2 and inducing Bax expression
In prior studies, we have shown (Cerda et al., 2001 ) and confirmed in the current studies ( , 4, and 6 (panels a, b, and c, respectively) were immunoprecipitated from total cell extracts (200 mg) from synchronized empty vector (EV) and PKC-d transfected cells. Indicated co-associating proteins were detected by Western blotting. Western blots that are representative of two independent experiments in duplicate are shown. Note the decreased cyclin E co-associating with cdk-2, decreased cyclin D1 co-associating with cdk-6, and increased p27
Kip1 co-associating with cdk-4 in PKC-d transfectants.
Mechanisms of action of tumor suppressor PKC-d SR Cerda et al overexpression increased programmed cell death in Caco-2 cells. Because the increased ratio of proapoptotic to antiapoptotic proteins is an important determinant of a cell's proclivity to apoptose, we characterized alterations in expression levels of members of the Bcl-2 family of proteins, key regulators of cell survival pathways (Potten et al., 1997) . As shown in Figure 11 , PKC-d transfectants exhibited a significant 50% decrease in expression of antiapoptotic protein, Bcl-2, and a significant 100% increase in expression of proapoptotic protein, Bax, as compared to EV control cells (note: Bax and Bcl-2 at zero time point, lanes 1 and 5). Consistent with an enhancement of apoptosis observed in phorbol ester-treated cells (Cerda et al., 2001) , TPA further decreased Bcl-2 expression B1.5-fold by 8 h of treatment in Caco-2 cells overexpressing PKC-d, in contrast to EV controls where expression of Bcl-2 was slightly increased (Figure 11, compare lanes 8 and 4) . Although proapoptotic Bak expression was remarkably increased upon phorbol ester treatment, there was no significant difference in expression of this protein between EV and PKC-d Caco-2 transfectants, suggesting that this proapoptotic member does not play a key role in PKC-d induced Caco-2 cell death (Figure 11 , compare lanes 2-4 with 6-8). In summary, PKC-d overexpression changes the apoptotic rate of Caco-2 colon cancer cells by increasing the ratio of proapoptotic Bax to antiapoptotic Bcl-2.
Real-time PCR analysis demonstrated that Bax mRNA was significantly increased two-fold in PKC-d transfectants, whereas Bcl-2 mRNA was unchanged (Figure 12 ). Compared with EV cells, Bax mRNA levels remained significantly higher in PKC-d transfectants upon TPA treatment (Figure 12 ). This is consistent with increased transcription of proapoptotic Bax in PKC-d transfectants. These results suggest that PKC-d-dependent decreases in Bcl-2 involve a post-transcriptional mechanism, whereas transcriptional mechanisms, and/or possibly mRNA stabilization, are involved in the PKC-d mediated increase in Bax expression.
PKC-d knockdown with specific siRNA oligonucleotides, but not irrelevant control sequences, inhibited Bax protein expression by more than 50% (Figure 13 , compare lanes 3 and 4 with 1 and 2), further supporting our conclusion that PKC-d enhances apoptosis through Bax upregulation.
Discussion
The colonic epithelium requires continuous renewal to replace cell loss (Shanmugathasan and Jothy, 2000) . The progenitor stem cells are localized in the crypt base. Daughter cells soon cease to divide and mature as they migrate upward. Colonocytes eventually apoptose as cells reach the colonic lumen. These colonic differentiation and cell death paradigms are regulated by multiple signaling pathways, including members of the PKC family (Weinstein, 1991; Klein et al., 2000) . Spatial and temporal changes in PKC-d expression and membrane association in normal rat intestinal and colonic epithelium suggest this isoform regulates normal differentiation and apoptosis in the GI tract (Saxon et al., 1994; Verstovsek et al., 1998; Klein et al., 2000) .
Colonic carcinogenesis is characterized by the progressive loss of homeostatic regulators (Lipkin, 1971; Moss et al., 1996; Shanmugathasan and Jothy, 2000) . Alterations in several PKC isoforms occur during colonic malignant transformation, including loss of PKC-d in neoplastic progression (Weinstein, 1991; DeRubertis, 1992, 1994; Davidson et al., 1994; Kahl-Rainer et al., 1994 McGarrity and Peiffer, 1994; Wali et al., 1995) . Caco-2 cells, derived from a human colon cancer, also show downregulation of PKC-d (Cerda et al., 2001; Banan et al., 2002) . These cells are widely employed to study mechanisms of colonocyte growth, maturation and cell death (Pinto et al., 1983; Evers et al., 1996; Gartel et al., 1996; Abraham et al., 1998; Ding et al., 1998) . Caco-2 cells express multiple PKC isoforms, which are thought to deliver distinct mitogenic and/or apoptotic signals in colon cancer cells (Sauma et al., 1996; Scaglione-Sewell et al., 1998; Chen et al., 1999; Weller et al., 1999; Perletti et al., 2005; Wang et al., 2006) . Our previous studies in Caco-2 transfectants, engineered to upregulate PKC-d, demonstrated that PKC-d inhibited cell growth, enhanced differentiation and accelerated apoptosis (Cerda et al., 2001) .
In the present study, we have successfully used these transfected Caco-2 cells, as well as Caco-2 cells with PKC-d knockdown by sequence specific siRNA, to dissect several growth-regulating pathways mediated by this isoform. Specifically, in this study, we have demonstrated that PKC-d overexpression in Caco-2 cells downregulated cyclin D1 and cyclin E, and upregulated G1 cdk co-associations with cyclin-cdk inhibitors, p21
Kip1
. PKC-d also decreased antiapoptotic Bcl-2 and increased proapoptotic Bax. To our knowledge, this is the first study demonstrating that PKC-d downregulates cyclin D1 and cyclin E expression in colon cancer cells. In addition, we have shown that PKC-d alters Bcl-2 and Bax expression in directions predicted to enhance apoptosis in Caco-2 cells. The current studies have thus extended our previous findings by elucidating several important underlying mechanisms by which PKC-d inhibits growth and enhances apoptosis in colon cancer cells.
Since PKC-d is increased in postmitotic differentiating colonocytes, we previously speculated and subsequently confirmed that this kinase inhibited Caco-2 cellular proliferation (see Figure 1 and Cerda et al., 2001) . Previously, we have demonstrated that short incubations of Caco-2 cells with phorbol esters (o60 min) did not downregulate PKC-d (Khare et al., 1999) . In the current study, we found that short-term treatment of Caco-2 cells with phorbol esters (o60 min), caused similar growth inhibition as long-term treatment (data not shown). Thus in our system, we infer that PKC-d activation, not downregulation, is sufficient to inhibit proliferation. This conclusion is in agreement with our fundamental hypothesis that PKC-d subserves a tumor suppressor role. Loss of PKC-d, as occurs in colonic tumorigenesis, would then be predicted to increase proliferation. Using siRNA to specifically inhibit expression of this enzyme, we found that PKC-d knockdown enhanced Caco-2 cell proliferation, consistent with our previous results that PKC-d upregulation (and activation) inhibited Caco-2 cell proliferation (see Figure 2 and Cerda et al., 2001) . These antiproliferative effects of PKC-d might reflect phase-specific or nonspecific cell cycle inhibition and/or acceleration of cell death. In the present study, we initially investigated PKC-d induced changes in the cell cycle. We demonstrated that upregulation of PKC-d slowed the G1-S transition upon agonist stimulation in Caco-2 cells (Table 1 ). In agreement with our findings, in many noncolonic cells, PKC-d is a negative regulator of G1-S transition (Jackson and Foster, 2004) . In contrast, in other cell types PKC-d promotes proliferation, indicating that PKC-d can mediate opposing effects determined by the cell context (Jackson and Foster, 2004) .
Since PKC-d upregulation inhibited G1 to S transition, we next examined several regulators of G1/S cell cycle control. We found PKC-d overexpression downregulated cyclin D1 and cyclin E protein expression in Caco-2 cells through post-transcriptional (cyclins D1 and E) and transcriptional (cyclin E) mechanisms (Figures 4 and 5) . This downregulation was a specific effect of PKC-d since knockdown of this isoform by sequence specific siRNAs increased the protein expression of these cyclins (Figure 6 ). This downregulation is in contrast to the TPA-induced increase in protein and mRNA expression of cyclin E, and to a lesser extent cyclin D1, seen in EV cells. We speculate cyclin D1 and E upregulation in EV cells is mediated by activation of other (non-PKC-d) phorbol ester-sensitive PKC isoforms that enhance cell cycle progression (Table 1) . TPA in fact increased S phase in EV but not in PKC-d transfectants. We believe these opposing effects in EV vs PKC-d transfectants occurred since PKC-d mediates a cell cycle slowing by increasing p21
Waf1 and decreasing cyclin D1 and E (Figures 4, 7 and 8) .
Cyclins D1 and E are overexpressed in a variety of tumors, including colon carcinomas (Bartkova et al., 1994; MacLachlan et al., 1995; Arber et al., 1996; Hosokawa and Arnold, 1998; Donnellan and Chetty, 1999; Jang et al., 1999; Milde-Langosch et al., 2000) . Numerous studies have confirmed the importance of these cyclins in promoting G1/S transit (Bartek and Lukas, 2001; Jones and Kazlauskas, 2001) , and their critical roles in cancer cell proliferation (Liu et al., 1995; Arber et al., 1997; Donnellan and Chetty, 1999) . Loss of cyclin D1, moreover, has been demonstrated to inhibit the growth and tumorigenicity of colon cancer cells (Arber et al., 1997) . Our studies are in agreement with previous findings in which PKC-d overexpression inhibited proliferation of vascular smooth muscle and capillary endothelial cells by suppressing cyclin D1 and cyclin E expression (Fukumoto et al., 1997; Ashton et al., 1999) . In contrast to our findings in Caco-2 cells, however, PKC-d has been shown to downregulate cyclin D1 expression at the transcriptional level in several noncolonic cell types (Page et al., 2002; Soh and Weinstein, 2003) . These differences emphasize the importance of understanding the control of cell cycle regulators by PKC-d in the context of colon cancer cells to elucidate its tumor suppressor role in the colon.
In addition to changes in cyclins D1 and E, G1 progression is regulated by coordinated actions of cyclin-dependent and cyclin-independent cdk inhibitors, including members of the CIP/KIP family (p21 Waf1 , p27
Kip1 and p57
Kip2
) and INK4 (p16, p19) proteins, as well as the retinoblastoma (pRb) and p53 tumor suppressor proteins (Akiyama et al., 1992; Dulic et al., 1994; King et al., 1996) . In intestinal epithelial cells, PKC agonist-mediated cell cycle arrest in the G1 phase was accompanied by accumulation of hypophosphorylated pRb and induction of p21
Waf1 and p27 Kip1 (Frey et al., 1997) . Consistent with a G1 cell cycle slowing observed in PKC-d transfected Caco-2 cells, we found that PKC-d upregulation reduced levels of cyclin D1-cdk6 and cyclin E-cdk2 complexes, and increased p21
Kip1 co-associating with cdk4 (Figures 9  and 10 ). These changes are predicted to decrease cyclincdk kinase activities and thereby contribute to the cell cycle slowing observed in PKC-d transfectants.
Compared to low p21 Waf1 expression in proliferating cells, levels of this cyclin-cdk inhibitor are high in nonproliferating and terminally differentiated cells of the mouse colon (Gartel et al., 1996) . Loss of p21
Waf1 can occur as early as dysplastic aberrant crypt foci, the earliest detectable histological abnormalities and putative precursors of colon cancer (Polyak et al., 1996) . We have demonstrated that PKC-d upregulates p21
Waf1 in Caco-2 cells since TPA treatment of PKC-d transfectants enhanced p21 Waf1 expression and caused a sustained increase in p21 Waf1 -cdk4 association, whereas rottlerin, a specific PKC-d inhibitor, suppressed this induction (Figures 7, 8 and 10) . Furthermore, knockdown of this isoform by sequence specific siRNAs blocked induction of the cyclin-cdk inhibitor (Figure 8 ). Our findings are in agreement with studies in noncolonic cell systems that have demonstrated a requirement for PKC-d in p21
Waf1 induction by phorbol esters (Zezula et al., 1997; Arita et al., 1998; Shanmugam et al., 2001; Nakagawa et al., 2005; Yokoyama et al., 2005) . Although TPA is a general activator of phorbol ester sensitive PKC isoforms, we attribute these effects to PKC-d in these transfectants since the endogenous nontargeted PKC isoforms did not differ in expression in EV or PKC-d transfectants, compared to parental Caco-2 cells (Cerda et al., 2001) . PKC-d upregulation also enhanced the steady-state mRNA levels of this cdk inhibitor in Caco-2 cells, indicating that PKC-d regulates p21
Waf1 by increasing transcription and/or stabilizing p21
Waf1 mRNA (Figure 7 ). This finding is consistent with the established role of transcription in regulating p21
Waf1 expression in Caco-2 cells (Evers et al., 1996; Gartel et al., 1996 Gartel et al., , 2000a . Loss of PKC-d in tumorigenesis might, therefore, contribute to the decreased p21
Waf1 expression observed in colonic carcinogenesis.
Recent studies by Perletti et al. (2005) have demonstrated that PKC-d requires the tumor suppressor p53 to inhibit growth and induce differentiation of HCT116 colon cancer cells by a p21
Waf1 -dependent mechanism. Depending on the cell context, however, p21
Waf1 can also induce growth arrest by p53-independent pathways (elDeiry et al., 1993; Zeng and el-Deiry, 1996; Cayrol et al., 1998) . In the case of Caco-2 cells, which are known to lack p53 (Djelloul et al., 1997) , we conclude that PKC-d inhibits cell cycling by a p53-independent p21
Waf1 -dependent pathway (Figures 7 and 8) . Several investigators have also demonstrated p21
Waf1 is induced during Caco-2 cell differentiation (Evers et al., 1996; Gartel et al., 1996 Gartel et al., , 2000b Abraham et al., 1998) . Since p53 is mutated or lost in many cancers, including nearly half of all colonic tumors (Baker et al., 1989) , identifying pathways that activate p21
Waf1 by p53-independent mechanisms have potentially important therapeutic implications. In this regard, p21 Waf1 induction by increased PKC-d signaling is a novel pathway that might be exploited in future chemopreventive and chemotherapeutic strategies. In this regard, in preliminary studies, we have found that chemopreventive fish oils (o-3 fatty acids) increased PKC-d expression, whereas tumor promoting o-6 fatty acids downregulated the expression of this isoform (Cerda et al., AGA proceedings 2005) . We anticipate future investigations in this area will identify new avenues for more selective and effective ways to preserve PKC-d, and thereby restrain the growth of transforming colonoytes.
In addition to the role of PKC-d as a negative regulator of cell cycle progression, we have previously demonstrated that this isoform enhanced the rate of Caco-2 cell apoptosis (Cerda et al., 2001) . To gain further insights into this proapoptotic effect, we investigated the molecular mechanisms governing PKC-d-mediated cell death in Caco-2 cells. Antiapoptotic Bcl-2 and proapoptotic proteins Bak and Bax are key mediators of apoptosis in colon cancer cells (Bronner et al., 1995; Ruemmele et al., 1999; Mandal et al., 2001 ). Current models suggest that ratios of antiapoptotic to proapoptotic members of the Bcl-2 family of proteins regulate the apoptotic potential of a cell (Boise et al., 1995) . We found that PKC-d upregulation suppressed Bcl-2 and induced Bax expression, thereby altering the ratio of these cell death regulators to favor apoptosis in Caco-2 cells (Figures  11-13 ). Our studies, thus, suggest that changes in Bcl-2 and Bax contribute to the proapoptotic signaling of PKC-d. These results are in agreement with previous studies that suggested this PKC isoform is a positive regulator of apoptosis in other colon cancer cells (Weller et al., 1999; McMillan et al., 2003; Perletti et al., 2005) . Similar effects were recently reported by Sitailo et al. (2004) in human keratinocytes, in which PKC-d-induced apoptosis was mediated by Bax upregulation.
PKC-d decreased Bcl-2 by a post-transcriptional mechanism, whereas this isoform increased Bax expression by mechanisms involving transcriptional activation, and/or mRNA stabilization. Moreover, PKC-d knockdown with specific siRNA oligonucleotides inhibited Bax protein expression, further confirming that PKC-d upregulates Bax. Expression patterns of Bcl-2 and Bax are spatially distinct. While Bcl-2 is expressed only in colonic crypt stem cells, where it could protect progenitor cells from DNA-damage induced apoptotic death, Bax expression is limited to maturing epithelial cells destined for programmed cell death at the colonic luminal surface (Krajewski et al., 1994; Potten et al., 1997) . Upregulation of Bcl-2 has been suggested to play a role in colorectal tumorigenesis, especially in the early phases of the adenoma-carcinoma sequence, and increased Bcl-2 expression is associated with a worse prognosis in colon cancer (Bosari et al., 1995; Bronner et al., 1995; Thompson, 1995) . In contrast, Bax-positive tumors have a significantly better prognosis and greater 5-year survival rates compared to Bax-negative tumors (Ogura et al., 1999) . Thus, PKC-d, by decreasing Bcl-2 and increasing Bax, would be predicted to serve a tumor suppressor role in colonic carcinogenesis. Bcl-2 and PKC-d also play antagonistic roles in other cells. For example, in murine myeloid cells, PKC-d blocked antiapoptotic functions of Bcl-2 overexpression, whereas in vascular smooth muscle cells, upregulated Bcl-2 inhibited PKC-d induced apoptosis (Barrett et al., 2002; Goerke et al., 2002) . These results indicate PKC-d and Bcl-2 mediate opposing cell survival paradigms in cell context-specific manners.
In conclusion, our experiments have uncovered two important molecular mechanisms governing cell cycle and cell death that contribute to the tumor suppressor function of PKC-d in human colonic carcinogenesis. Our findings are summarized in Figure 14 . Firstly, PKC-d suppresses G1-S progression by inhibiting levels of Figure 14 Proposed model for PKC-d antiproliferative functions in Caco-2 cells. PKC-d signaling suppresses G1-S progression by inhibiting the expression levels of G1 cell cycle activators, cyclin D1 and cyclin E, and upregulating G1 cell cycle inhibitor p21
Waf1 as well as p27
Kip1 -cdk4 complex. PKC-d signals also inhibit cell survival by downregulating antiapoptotic Bcl-2 and increasing proapoptotic Bax. These tumor suppressor pathways inhibit mitogenic signaling and enhance cell death that result in decreased cellular proliferation of colon cancer cells.
G1 cell cycle activators, cyclin D1 and cyclin E, and upregulating G1 cell cycle inhibitor p21
Waf1 and enhancing p27
Kip1 co-association with cdk4. Secondly, PKC-d inhibits cell survival by downregulating antiapoptotic Bcl-2 and increasing pro-apoptotic Bax. We conclude that PKC-d inhibits mitogenic signaling and enhances cell death in colon cancer cells via these pathways. The observed loss of this tumor suppressor in transforming colonocytes would be predicted, therefore, to provide a clear growth advantage, contributing to the dysregulated growth characterizing colonic carcinogenesis. Our future efforts will focus on identifying PKC-d substrates that mediate these tumor suppressor effects.
Materials and methods

Materials
Tissue culture reagents were obtained from Fisher Scientific (Springfield, NJ, USA), and media supplements were from GIBCO BRL-Life Technologies (Gaithersburg, MD, USA). The mouse monoclonal antibody to human PKC-d protein used for Western blotting was from Signal Transduction Labs (Lexington, KY, USA). Protein A/G PLUS-Agarose beads, mouse monoclonal antibody to Bcl-2, and rabbit polyclonal antibodies to human Bax, cyclin D1, cyclin E, PKC-d and -z were from Santa Cruz Biotechnology (Santa Cruz, CA, USA (Austin, TX, USA). All other reagents used in this study were from Sigma Chemical or Fisher Scientific, unless otherwise indicated, and were of the highest purity available.
Preparation of zinc-depleted medium Zinc-depleted medium was prepared by a modification of the method by Palmiter (1994) , as previously described by our laboratory (Cerda et al., 2001 ).
Cell culture
Caco-2 cells were obtained from ATCC and low passage cells (passages 21-31) were cultured at 371C in a humidified atmosphere of 5% CO 2 -95% air, as previously described by our laboratory . PKC-d inducible stable transfectants were prepared as previously described (Cerda et al., 2001) . In the presence of Zn 2 þ , PKC-d transfectants upregulated PKC-d protein B4-fold and demonstrated B2-fold increase in PKC-d-specific kinase activity, compared with EV transfected control cells (Cerda et al., 2001) . Cells are routinely maintained in standard Dulbecco's minimum essential medium (DMEM) containing 4.5 g/l glucose, 10 mM HEPES (pH 7.4), 2 mM L-glutamine, 50 U/ml penicillin G, 50 mg/ml streptomycin, 2 mg/ml gentamicin, 1% essential and nonessential amino acids, and 20% fetal bovine serum (FBS). Stable transfectants were maintained in zincdepleted medium containing 400 mg/ml of G418 (Cerda et al., 2001) . To induce expression of PKC-d in these clones, EV and PKC-d transfected Caco-2 cells were cultured in Chelextreated DMEM supplemented with 175 mM Zn 2 þ , a nontoxic concentration of zinc that activates the metallothionein promoter. Maximal induction of this gene is achieved by 24-48 h.
Western blotting
Total cell lysates were prepared from treated cells and boiled for 3 min in 2 Â Laemmli SDS buffer (Laemmli, 1970) . Protein was assayed by the Bio-Rad Detergent Compatible protein assay using BSA as the standard. Equal amounts of protein (15-50 mg/lane) were separated by sodium dodecyl sulfatepolyacrylamide electrophoresis (SDS-PAGE), as described by Laemmli (1970) , and transferred onto Immobilon-P membranes (Millipore, Bedford, MA, USA). Nonspecific binding of antibodies was blocked by incubating blots at room temperature for 3 h with 5% non-fat dry milk in TBST (Trisbuffered saline in 0.05% Tween-20). After blocking, blots were processed for immunoblotting by overnight incubation at 41C with primary antibodies in TBST-5% milk. For phosphospecific antibodies, TBST-5% BSA was used to block nonspecific binding of antibodies and TBST-3% BSA was used for immunoblotting procedures. After incubation, blots were rinsed and incubated with appropriate (monoclonal vs polyclonal) peroxidase-conjugated secondary antibodies. Proteins were detected using an ECL system followed by xerography on X-OMAT AR film, as recommended by the manufacturer. The xerograms were scanned with a JX-3F6 scanner (Sharp Electronics, Mahwah, NJ, USA), and quantified using IP lab gel software (Signal Analytics, Vienna, VA, USA). Exposure times were adjusted to ensure a linear response.
Measurement of the abundance of G1 cyclin-cdk protein complexes, cyclin D1-cdk 4,6 and cyclin E-cdk 2 Immunoprecipitation of kinase complexes using specific antibodies were performed as previously described by our laboratory (Scaglione-Sewell et al., 2000) . Briefly, EV and PKC-d cDNA transfected Caco-2 cells were seeded at a density of 5 Â 10 5 cells in Falcon 60 mm tissue culture dishes and grown in zinc-depleted medium for 2 days. Induction of PKCd expression was initiated by replacing medium with Chelextreated DMEM medium containing 175 mM Zn 2 þ . Following a 48 h induction, treated cells were washed with PBS and lysed in 300 ml lysis buffer containing 50 mM HEPES (pH 7.5), 150 mM NaCl, 1 mM DTT, 2.5 mM EGTA, 0.1% Tween-20, 10% glycerol, 0.1 mM PMSF, 10 mg/ml leupeptin, 20 U/ml aprotinin, 10 mM b-glycerophosphate, 0.1 mM sodium orthovana-date, and 1 mM NaF. Cells were lysed on ice for 30 min, sonicated briefly, and centrifuged at 10 000 Â g for 15 min to remove insoluble debris. Lysates (50 mg protein) were precleared with 1 mg of normal rabbit serum and 20 ml of protein A/G sepharose and incubated overnight with 5 ml antibodies to cdk2, cdk4, or cdk6 in a rocking platform at 41C. Protein A/G PLUS-Agarose beads (30 ml) were added to lysates and incubated for an additional 3 h at room temperature in a rocking platform. After four washes in lysis buffer, agarose beads were resuspended in 2 Â Laemmli buffer and boiled for 5 min to release immunoprecipitated proteins. Proteins were separated by SDS-PAGE on a 12 or 15% resolving gels, and electroblotted to polyvinylidene difluoride membranes. Comparable levels of kinase abundance were confirmed by probing lysates for cdk expression levels. mRNA isolation and quantification by real-time PCR Total RNA was isolated from treated cells using the RNAeasy Kit (Quiagen), according to the manufacturer's protocol. RNA was dissolved in DEPC-treated water and genomic DNA removed by DNase-I using the DNA-freet kit. RNA was stored in RNase free conditions at À801C until further use. A real-time PCR-based assay using Taqman probes was used to quantify the levels of mRNA as previously described with several modifications (Schmittgen et al., 2000) . Briefly, RNA was reverse transcribed in a 20 ml reaction containing 1 mg of RNA, 5 mM MgCl 2 , 1Â PCR Buffer II, 4 mM dNTPs (deoxyribonucleotide triphosphates: dATP, dGTP, dCTP, dTTP), 20 U of RNase inhibitor, 2.5 mM random hexamers, and 50 U of Moloney murine leukemia virus reverse transcriptase. Samples were reverse-transcribed in a PTC-100 thermal cycler at 421C for 60 min and the temperature then increased to 951C for 5 min to denature the reverse transcriptase. For real-time PCR, each reaction contained 5 ml of a 1:5 dilution of the cDNA, 1 Â PCR Buffer II, 5.5 mM MgCl 2 , 200 mM dNTPs, 200 nM of forward and reverse primers, 100 nM of Taqman probe, 0.75 U of HotStarTaqt DNA polymerase, and water added to adjust the final volume to 25 ml. The reactions were incubated at 951C for 15 min to activate the DNA polymerase followed by 45 cycles of 15 s at 951C and 60 s at 601C. To normalize for total RNA, glyceraldehyde-3-phosphate dehydrogenase (GAPDH) was used as internal control gene in our samples. In preliminary experiments, PCR products of the expected sizes were visualized on an agarose gel and their predicted sequences confirmed by DNA sequencing. All primers were designed using computer software to optimize amplification of specific cDNA sequences and checked for binding against nontargeted genes using the available genomic sequences in the database. Sequences for primers and Taqman probes used for real-time PCR were as follows (5 0 to 3 0 ): cyclin D1: TGCGAGGAACAGAAGTGCG (forward primer), AGCTGCAGGCGGCTCTT (reverse primer), TCCTGTCGCTGGAGCCCGTGAA (Taqman Probe); cyclin E: CTCCAGGAAGAGGAAGGCAA (forward primer), TCGATTTTGGCCATTTCTTCA (reverse primer), CGTGAC CGTTTTTTTGCAGGATCC (Taqman Probe); p21: GACTC TCAGGGTCGAAAACG (forward primer), GGATTAGGG CTTCCTCTTGG (reverse primer), CATGACAGATTTCTAC CACTCCAAACGCC (Taqman Probe); Bax: GTCGCCCTTT TCTACTTTGC (forward primer), GGAGGAAGTCCAA TGTCCAG (reverse primer), CCAAGGTGCCGGAACTGAT CAGAAC (Taqman Probe); Bcl-2: GGATTGTGGCCTTC TTTGAG (forward primer), GCCGGTTCAGGTACTCAG TC (reverse primer), CGGTTGACGCTCTCCACACACATG (Taqman Probe). cDNA samples from EV and PKC-d clones were synthesized in parallel reactions, along with negative controls for which reverse transcriptase was omitted from the reaction. PCR reactions were run in triplicate, and mRNA levels were expressed as relative changes after normalization to GAPDH mRNA abundance.
Preparation and transfection of short interfering RNAs (siRNAs) targeting PKC-d RNA interference (RNAi), the targeted mRNA degradation induced by double-stranded RNA (dsRNA), was used as a complementary technique to our overexpression systems to analyse PKC-d function. We used siRNAs targeting human PKC-d, which have been confirmed to successfully inhibit PKC-d mRNA by more than 80% (Irie et al., 2002) , following the methods described for siRNAs applicable to cultured mammalian cells (Elbashir et al., 2001) . Briefly, 21 nucleotide RNAs, containing 3 0 overhangs of 2 0 -deoxythymidine, were chemically synthesized by Ambion Inc. PKC-d siRNA sequences, corresponding to nucleotides 603-621 after the start codon, were as follows: 5 0 -CGAGAAGAUCAUCGG CAGATT-3 0 and 5 0 -UCUGCCGAUGAUCUUGUCGTT-3 0 . Duplexes of siRNAs were generated by incubating 20 mM sense and antisense strands in annealing buffer (100 mM potassium acetate, 30 mM HEPES-KOH pH 7.4, and 2 mM magnesium acetate) for 1 min at 901C to denature, followed by a 1 h incubation at 371C to renature. EV and PKC-d overexpressing Caco-2 cells were transfected with 100 nM PKC-d specific RNAi 21-nt duplex or a scrambled control, using siPORT transfection reagent (Ambion). After 72 h, cells were lysed and proteins (20 mg) assayed for PKC-d other PKC isoforms, and b-actin. We achieved more than 80% downregulation of PKCd expression under these conditions whereas other PKC isoforms were unchanged. Lysates were used to probe for protein expression by Western blotting.
Formazan and BrdU-based cell proliferation assays EV and PKC-d transfectants were plated onto 96-well microtiter tissue culture plates in zinc-depleted DMEM medium containing 400 mg/ml G418 at a density of 5 Â 10 3 cells/well. Following a 24-h period of zinc pretreatment, cells in replicates of six were treated with 100 nM of either the PKC agonist, phorbol 12-myristate 13-acetate (TPA), or the PKC-d-specific activator, BisA, in the presence of 175 mM Zn 2 þ for an additional 48 h. Groups treated with DMSO alone were used as vehicle controls. For RNAi experiments, Caco-2 cells were treated with 50 or 100 nM PKC-d-specific RNAi or scrambled control oligonucleotides using siPORT transfection reagent. Effects of PKC agonists or siRNA on cell growth were detected using two separate colorimetric assays for the quantification of cell proliferation; the formazan assay and the BrdU cell proliferation assay (Roche Molecular Biochemicals, IN, USA). The formazan assay is based on the cleavage of the tetrazolim salt Wst-1 by mitochondrial dehydrogenases in viable cells. The BrdU colorimetric immunoassay is a quantitative cell proliferation assay based on the measurement of BrdU incorporation during DNA synthesis. After treatments, 10 ml/well of Wst-1 reagent or 20 ml/well of BrdU were added to each well, followed by an incubationof 0.5-4 h at 371C. The formazan dye produced by metabolically active cells was quantified by measuring absorbance of samples on a scanning multiwell spectrophotometer (ELISA reader) using a 450 nm filter. For the BrdU assay, cells were fixed and the DNA denatured. Anti-BrdU-peroxidase immune complexes were detected by substrate reaction and quantified in an ELISA reader at 370 nm. We found that Wst-1 and BrdU incorporation gave comparable results for cell proliferation.
Cell cycle analysis by flow cytometry EV and PKC-d cDNA transfected Caco-2 cells were seeded in six-well tissue culture dishes at a density of 1 Â 10 5 cells/well in zinc-depleted medium and allowed to attach overnight. PKC-d induction was initiated by replacing medium in triplicate wells with Chelex-treated DMEM medium containing 175 mM Zn 2 þ for a period of 48 h. This was followed by treatment of cells with 100 nM of either TPA or 100 nM BisA, or DMSO control for 6-24 h in the presence of zinc. At 6, 15 and 24 h of treatment, the distribution cells in the cell cycle were assessed according to the method of Darzynkiewicz (1994) , as previously described by our laboratory (Cerda et al., 2001) .
Assessment of apoptosis EV and PKC-d transfectants were seeded at a density of 1.5 Â 10 5 cells in Nunc polystyrene slideflasks (Nunc, Naperville, IL, USA) and grown in zinc-depleted medium for two days. Preconfluent cells were then treated for a period of 48 h in Chelex-treated DMEM supplemented with 175 mM Zn 2 þ in the presence of 100 nM of either TPA or 100 nM BisA, or vehicle (DMSO, 0.05%). Cells were washed twice with HBSS and fixed for 10 min at room temperature with 4% paraformaldehyde in PBS. Fixative was removed by aspiration and the monolayer washed twice in PBS. DNA was stained for 1 min with 2 mg/ml 4 0 ,6-diamidino-2-phenylindole dihydrochloride (DAPI; Molecular Probes, Eugene, OR, USA) at room temperature. Excess DAPI stain was removed and the monolayer was extensively washed with water and a coverslip mounted with Vectashieldt mounting medium (Vector Laboratories, Burlingame, CA, USA). Stained nuclei were viewed at Â 200 using an Olympus BH-2 fluorescence microscope (Olympus Optical Co., Ltd, Japan) with the UV cube in position. Apoptotic nuclei, as assessed by nuclear condensation and fragmentation, were quantified in 1000 random cells in duplicate platings per sample for each experiment, as previously described by our laboratory (Cerda et al., 2001) . Rates of apoptosis were expressed as a mean percentage7s.d. (apoptotic nuclei/total nuclei Â 100).
Statistical analysis
Numerical data are expressed as means7s.d. Statistical significance of the differences between samples was determined by unpaired Student's t-test. Data were considered significantly different at the level of Po0.05.
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